Table 2 Real-world studies
From: Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME
Study | Disease | Study Design | Number of Eyes (Faricimab) | Number of Patients (Faricimab) | Number of Injections | Key Findings |
|---|---|---|---|---|---|---|
TAHOE (9) | DME | Investigator-initiated real-world study | 181 | 136 | 756 | After 3 injections, mean improvement of + 3.78 letters and reduction in CST of -45.28 µm. No reported intraocular inflammation |
FARETINA-DME (9,10) | DME | Real-world study, using IRIS registry data | 3961 | 2692 | Â | After 4 injections, stable vision in previously treated patients and a mean improvement of 3 letters in previously untreated patients |
FARWIDE-DME (11) | DME | Observational, non-controlled study in the UK | 2673 | 1921 |  | After 4 injections, around 64% of previously treated eyes and 44% of untreated eyes achieved treatment intervals ≥ 8 weeks |
Rush (12) | DME | Observational, non-controlled study | 51 | 51 | Â | Aflibercept-resistant patients switched to faricimab; 39% with a dry macula at 12 months; -0.13 logMAR improvement |
Kusuhara (13) | DME | Observational, non-controlled study | 21 | 19 | Â | No statiscally signifcant improvement |
TRUCKEE (15, 16) | nAMD | Investigator-initiated real-world study | 2622 | 2212 | 11450 | After the first injection, mean improvement of + 1.1 letters and reduction in CST of -31.3 µm. Two cases of idiopathic ocular inflammation reported |
FARETINA-nAMD (17) | nAMD | Real-world study, using IRIS registry data | 12.119 | 10551 | Â | After 4 injections, mean improvement of 0.5 letters in previously treated patients and 1.6 letters in untreated patients |
FARWIDE-nAMD (18) | nAMD | Observational, non-controlled study in the UK | 3564 | 2987 | Â | Â |
Rush and Rush (19) | nAMD | Case-control study | Â | 27 | Â | Comparison with aflibercept. Higher improvement in the switch group from aflibercept to faricimab |
Leung (20) | nAMD | Observational, non-controlled study in Atlanta, GA |  | 190 |  | After 3 injections, -0.06 logMAR improvement and − 25 µm CST reduction |
Mukai (21) | nAMD | Observational, non-controlled study in Japan | 63 | 61 | Â | 82% of the eyes achieved a dry macula at month 3 |
Matsumoto (22) | nAMD | Observational, non-controlled study in Japan | 40 | 38 | Â | LogMAR improvement of -0.11; dry macula in 79.5%; and complete polupoidal resolution in 61.1% of the eyes |
Cheng (24) | nAMD | Observational, non-controlled study | Â | 13 | Â | Â |
Stanga (23) | nAMD | Observational, non-controlled study | Â | 11 | Â | Â |